Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Blocking C3d(+)/GFAP(+) A1 astrocyte conversion with Semaglutide attenuates blood-brain barrier disruption in mice after ischemic stroke
The goal of this study was to establish a tumor model for GLP-1 receptor targeting and to use a newly designed exendin-4DTPA (DTPA is diethylenetriaminepentaacetic acid) conjugate for GLP-1 receptor targeting
Information on reagents, antibodies, plasmids, and other materials used in this study can be found in the Supplemental Lists of Resources
For acute injuries like recent muscle strains or ligament sprains, 4 to 6 weeks of daily administration followed by 2 to 4 week breaks represents the consensus approach
US$ 28.36
US$ 27.98
US$ 25.23
US$ 25.26
